The global demand for Preimplantation Genetics Diagnosis (PGD) Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028.
Preimplantation genetic diagnosis (PGD) identifies genetic abnormalities or defects in preimplantation embryos before embryo transfer. The diagnostic serves to prevent transmission of certain genetic diseases or disorders on to the child, so only unaffected embryos are established from in vitro fertilization (IVF). Individuals with carriers of sex-linked genetic diseases and single-gene disorders, chromosomal disorders, women age 35 and over, women experiencing recurrent pregnancy loss, and women with more than one failed fertility treatment are possible candidates for PGD.
Market Dynamics
The global preimplantation genetics diagnosis (PGD) market is projected to grow significantly during the forecast period owing to the rising incidences of hereditary, genetic, and chromosomal diseases. PGD is evolving as a promising technique to prevent the substantial risk of transmitting a severe genetic disorder to their offspring. The market is projected to see gradual growth owing to rising warenes about its benefits. Significant improvements in PGD analysis, such as fluorescence in situ hybridization (FISH), to newer molecular tools, such as DNA microarrays and next-generation sequencing will create new opportunities for the market. However, the high costs incurred in the PGD procedure hinder the growth of the market. Moreover, ethical concerns also obstruct the growth of the market.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of preimplantation genetics diagnosis (PGD).
Market Segmentation
The entire preimplantation genetics diagnosis (PGD) market has been sub-categorized into test type. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Test Type
- Chromosomal Abnormalities
- Gender Selection
- X-linked Diseases
- Aneuploidy
- Single Gene Disorders
- Others
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for preimplantation genetics diagnosis (PGD) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Preimplantation Genetics Diagnosis (PGD) Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the preimplantation genetics diagnosis (PGD) market include Reprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., Reproductive Genetics Innovations LLC. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.